{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:59:19Z","timestamp":1792155559668,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["no. 81471759"],"award-info":[{"award-number":["no. 81471759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00270-019-02406-3","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T21:11:42Z","timestamp":1579813902000},"page":"996-1005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization\/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis"],"prefix":"10.1007","volume":"43","author":[{"given":"Jungang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqiang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanglian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baocai","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"key":"2406_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62\u20137.","journal-title":"Hepatology"},{"key":"2406_CR2","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.4254\/wjh.v7.i11.1553","volume":"7","author":"SJ Yu","year":"2015","unstructured":"Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol. 2015;7:1553\u201361.","journal-title":"World J Hepatol"},{"key":"2406_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000327577","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339\u201364.","journal-title":"Dig Dis"},{"key":"2406_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5009\/gnl.2013.7.6.696","volume":"7","author":"SW Jeong","year":"2013","unstructured":"Jeong SW, Jang JY, Shim KY, et al. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver. 2013;7:696\u2013703.","journal-title":"Gut Liver"},{"key":"2406_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","volume":"82","author":"JH Choi","year":"2018","unstructured":"Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469\u201378.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2406_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","volume":"65","author":"T Kokudo","year":"2016","unstructured":"Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938\u201343.","journal-title":"J Hepatol"},{"key":"2406_CR7","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.2147\/CMAR.S166527","volume":"10","author":"WF Lv","year":"2018","unstructured":"Lv WF, Liu KC, Lu D, et al. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res. 2018;10:4719\u201326.","journal-title":"Cancer Manag Res"},{"key":"2406_CR8","doi-asserted-by":"publisher","first-page":"e0154986","DOI":"10.1371\/journal.pone.0154986","volume":"11","author":"YY Cho","year":"2016","unstructured":"Cho YY, Lee M, Kim HC, et al. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS ONE. 2016;11:e0154986.","journal-title":"PLoS ONE"},{"key":"2406_CR9","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1111\/ajco.12606","volume":"13","author":"H Liang","year":"2017","unstructured":"Liang H, Cui P, Guo Q, et al. Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. Asia Pac J Clin Oncol. 2017;13:e331\u201341.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2406_CR10","doi-asserted-by":"publisher","first-page":"79816","DOI":"10.18632\/oncotarget.19767","volume":"8","author":"J Sun","year":"2017","unstructured":"Sun J, Shi J, Huang B, et al. The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization. Oncotarget. 2017;8:79816\u201324.","journal-title":"Oncotarget"},{"key":"2406_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000367746","volume":"4","author":"S Obi","year":"2015","unstructured":"Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver cancer. 2015;4:188\u201399.","journal-title":"Liver cancer"},{"key":"2406_CR12","first-page":"743","volume":"20","author":"A Del Freo","year":"2006","unstructured":"Del Freo A, Fiorentini G, Sanguinetti F, et al. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo (Athens, Greece). 2006;20:743\u20136.","journal-title":"In Vivo (Athens, Greece)"},{"key":"2406_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1148\/radiol.2016160572","volume":"283","author":"X Wang","year":"2017","unstructured":"Wang X, Hu J, Cao G, et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma. Radiology. 2017;283:580\u20139.","journal-title":"Radiology"},{"key":"2406_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","volume":"67","author":"N Lyu","year":"2018","unstructured":"Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma. Gut. 2018;67:395\u20136.","journal-title":"Gut"},{"key":"2406_CR15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00270-017-1874-z","volume":"41","author":"MK He","year":"2018","unstructured":"He MK, Zou RH, Li QJ, et al. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc Intervent Radiol. 2018;41:734\u201343.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2406_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2406_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cncr.10694","volume":"95","author":"E Ando","year":"2002","unstructured":"Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588\u201395.","journal-title":"Cancer"},{"key":"2406_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40644-019-0202-z","volume":"19","author":"J Hu","year":"2019","unstructured":"Hu J, Zhu X, Wang X, Cao G, Wang X, Yang R. Evaluation of percutaneous unilateral trans-femoral implantation of side-hole port-catheter system with coil only fixed-catheter-tip for hepatic arterial infusion chemotherapy. Cancer Imaging. 2019;19:15.","journal-title":"Cancer Imaging"},{"key":"2406_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1471-2407-7-69","volume":"7","author":"B Hildebrandt","year":"2007","unstructured":"Hildebrandt B, Pech M, Nicolaou A, et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a phase II-study and historical comparison with the surgical approach. BMC Cancer. 2007;7:69.","journal-title":"BMC Cancer"},{"key":"2406_CR20","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1002\/cncr.25277","volume":"116","author":"AM Tsimberidou","year":"2010","unstructured":"Tsimberidou AM, Fu S, Ng C, et al. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010;116:4086\u201394.","journal-title":"Cancer"},{"key":"2406_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/01.cad.0000198912.98442.cd","volume":"17","author":"B Qin","year":"2006","unstructured":"Qin B, Tanaka R, Shibata Y, et al. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. Anticancer Drugs. 2006;17:445\u201353.","journal-title":"Anticancer Drugs"},{"key":"2406_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/jcp.27324","volume":"234","author":"J-C Wang","year":"2019","unstructured":"Wang J-C, Xia A-L, Xu Y, Lu X-J. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062\u201370.","journal-title":"J Cell Physiol"},{"key":"2406_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3348\/kjr.2018.0496","volume":"20","author":"PH Kim","year":"2019","unstructured":"Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. Korean J Radiol. 2019;20:385\u201398.","journal-title":"Korean J Radiol"},{"key":"2406_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00270-019-02346-y","volume":"43","author":"L Zhang","year":"2020","unstructured":"Zhang L, Hu B, Li W, et al. 125I irradiation stent for hepatocellular carcinoma with main portal vein tumor thrombosis: a systematic review. Cardiovasc Interv Radiol. 2020;43:196\u2013203.","journal-title":"Cardiovasc Interv Radiol"},{"key":"2406_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3350\/cmh.2016.22.1.160","volume":"22","author":"JM Lee","year":"2016","unstructured":"Lee JM, Jang BK, Lee YJ, et al. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016;22:160\u20137.","journal-title":"Clin Mol Hepatol"},{"key":"2406_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1148\/radiol.14131946","volume":"272","author":"K Zhu","year":"2014","unstructured":"Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2014a retrospective controlled study. Radiology. 2014;272:284\u201393.","journal-title":"Radiology"},{"key":"2406_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","volume":"16","author":"CS Georgiades","year":"2005","unstructured":"Georgiades CS, Hong K, D\u2019Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol JVIR. 2005;16:1653\u20139.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"2406_CR28","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57:1826\u201337.","journal-title":"Hepatology"},{"key":"2406_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00259-015-3210-7","volume":"43","author":"J Edeline","year":"2016","unstructured":"Edeline J, Crouzet L, Campillo-Gimenez B, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2016;43:635\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2406_CR30","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.2217\/fon.15.267","volume":"11","author":"R Golfieri","year":"2015","unstructured":"Golfieri R, Mosconi C, Cappelli A, et al. Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. Future Oncol (London, England). 2015;11:3133\u201342.","journal-title":"Future Oncol (London, England)"},{"key":"2406_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.crad.2013.09.009","volume":"69","author":"JM Theysohn","year":"2014","unstructured":"Theysohn JM, Ertle J, Muller S, et al. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol. 2014;69:172\u20138.","journal-title":"Clin Radiol"},{"key":"2406_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458\u201368.","journal-title":"Liver Cancer"},{"key":"2406_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000367737","volume":"4","author":"CC Lin","year":"2015","unstructured":"Lin CC, Hung CF, Chen WT, Lin SM. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4\u00a0weeks of treatment. Liver cancer. 2015;4:228\u201340.","journal-title":"Liver cancer"},{"key":"2406_CR34","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2013.542","volume":"109","author":"K Nouso","year":"2013","unstructured":"Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109:1904\u20137.","journal-title":"Br J Cancer"},{"key":"2406_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573\u201384.","journal-title":"Nat Rev Cancer"},{"key":"2406_CR36","first-page":"677","volume":"17","author":"B Melichar","year":"2012","unstructured":"Melichar B, Ferko A, Krajina A, et al. Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma. J BUON. 2012;17:677\u201383.","journal-title":"J BUON"},{"key":"2406_CR37","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.3747\/co.21.1577","volume":"21","author":"PJ Karanicolas","year":"2014","unstructured":"Karanicolas PJ, Metrakos P, Chan K, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol (Toronto, Ont). 2014;21:e129\u201336.","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"2406_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","volume":"18","author":"J Luo","year":"2011","unstructured":"Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413\u201320.","journal-title":"Ann Surg Oncol"},{"key":"2406_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-230X-14-84","volume":"14","author":"T Nakazawa","year":"2014","unstructured":"Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84.","journal-title":"BMC Gastroenterol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-019-02406-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-019-02406-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-019-02406-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T17:23:54Z","timestamp":1665595434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-019-02406-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1007\/s00270-019-02406-3","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]},"assertion":[{"value":"20 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this retrospective study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval Statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}}]}}